첨단 바이오테크 기업 Cellino와 물질이전계약(MTA) 체결KarisBio Signs Material Transfer Agreement (MTA) with Cellino, to Advance Automated Manufacturing of iPSC-derived Cell Therapies and Expand into Global Markets
세계최초 유도만능줄기세포 기반의 혈관내피세포 임상개발을 진행하고 있는 카리스바이오는 자율형 바이오 제조기술 선도 기업인 셀리노(Cellino)와 MTA를 체결하여, 세포치료제 생산자동화 및 글로벌 시장확장을 위한 초석을 마련했습니다.
한편, 하버드 공학 박사들이 설립한 셀리노는 Bayer 및 MIT 벤처 펀드 등의 투자를 받았으며 Forbes 등에서 주목받는 혁신 기업으로 선정된 미국 첨단 바이오 산업의 최전선에 있는 회사입니다.
[News 보기]
카리스바이오, 셀리노와 MTA 체결.. iPSC 치료제 생산 자동화 나서 – 머니투데이
KarisBio, the first in the world to advance clinical development of induced pluripotent stem cell (iPSC)-based vascular endothelial cell therapy, announced that it has signed a Material Transfer Agreement (MTA) with Cellino, a leading company in autonomous biomanufacturing technology, laying the foundation for automation in cell therapy production and global market expansion.
Meanwhile, Cellino, founded in 2017 in Boston, USA, is developing automated, large-scale production technology for iPSCs using AI and opticallaser-based systems. The company secured $80 million in Series A funding in 2022 and was awarded approximately $25 million in research funding in 2024 from ARPA-H (Advanced Research Projects Agency for Health) under the U.S. Department of Health and Human Services, placing it at the forefront of the U.S. advanced biotech industry.
